Enablex (darifenacin) dosing, indications, interactions, adverse effects, and more , , , Enablex (darifenacin) dosing, indications, interactions, adverse effects, and more, , , , , , , , , , , , , , , , , Edition:EnglishFrançaisDeutsch, Search, , No Results, News & Perspective, Drugs & Diseases, CME & Education, Log In, Register, , , , , https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL3JlZmVyZW5jZS5tZWRzY2FwZS5jb20vZHJ1Zy9lbmFibGV4LWRhcmlmZW5hY2luLTM0Mjg1MA==, , , processing.... , , , , , darifenacin (Rx)Brand and Other Names:Enablex, Classes: Anticholinergics, Genitourinary, , Dosing & Uses, Interactions, Adverse Effects, Warnings, Pregnancy, Pharmacology, Images, Patient Handout, Formulary, Dosing & Uses, AdultPediatric, Dosing Forms & Strength, , tablet, extended release, , 7.5mg, , 15mg, , , Overactive Bladder, , Indicated for overactive bladder with symptoms of urge incontinence, urgency, and frequency, , Initial: 7.5 mg PO qDay, , May be increased to 15 mg based on patient response as early as 2 weeks later, , Do not increase dose if taking concomitant CYP3A4 inhibitors, , Hepatic Impairment, , Moderate: Do not exceed initial dose of 7.5 mg/day, , Severe: Not recommended, , Administration, , Swallow with water, do not crush, chew or cut, , Safety and efficacy not established, Interactions, Interaction Checker, darifenacin and , No Results, No Interactions Found, Interactions Found, Contraindicated, Serious - Use Alternative, Significant - Monitor Closely, Minor, Sort by : , , Adverse Effects, , >10%, , Dry mouth (19-35%), , Constipation (15-21%), , , 1-10%, , Abdominal pain (2-4%), , Dizziness (2%), , Dry eyes (2%), , Dyspepsia (3-8%), , Nausea (2-4%), , UTI (4-5%), , Vaginitis (>1%), , Back pain (>1%), , Rhinitis (>1%), , Abnormal vision (>2%), , Vomiting (>1%), , Weight gain (>1%), , Flu-like syndrome (1-3%), , Peripheral edema (>1%), , , Postmarketing Reports, , Dermatologic: Erythema multiforme, interstitial granuloma annulare, , General: Hypersensitivity reactions, including angioedema with airway obstruction and anaphylactic reaction; hallucinations, , Cardiovascular: Palpitations, , , Warnings, , Contraindications, , Urinary retention, , Uncontrolled narrow-angle glaucoma, , Severe hepatic impairment, , Paralytic ileus, , GI or Gu obstruction, , Hypersensitivity, , , Cautions, , Bladder outflow obstruction, controlled narrow-angle glaucoma, decreased GI motility, renal/hepatic impairment, , Angioedema of the face, lips, tongue, and/or larynx have been reported, in some cases angioedema occurred after the first dose, , CNS anticholinergic effects reported including headache, confusion, hallucinations, and somnolence, , Heat prostration may occur in the presence of increased environmental temperature , , Use caution in patients with decreased GI motility, hiatal hernia, reflux esophagitis, and ulcerative colitis, , Use caution in patients with controlled narrow-angle glaucoma and patients with hepatic impairment, or myesthenia gravis, , , Pregnancy & Lactation, , Pregnancy Category: C, , Lactation: Excretion in milk unknown; use caution, , Pregnancy Categories, A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA:Information not available. more... Pharmacology, , Mechanism of Action, , Competitive muscarinic receptor antagonist of the M3 muscarinic receptor; receptor blocking limits bladder contractions, and reduce symptoms of bladder irritability/overactivity, , , Absorption, , Protein Bound: 98%, , Vd: 163 L, , Peak plasma time: 7 hr, , , Metabolism, , Liver, by CYP3A4 and CYP2D6, , , Elimination, , Half-Life: 13-19 hr, , Excretion: 60% urine; 40% feces, , , Images, , Patient Handout, Print w/ Office Info, Print w/out Office Info, , Formulary, FormularyPatient Discounts, To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. Create Your List of Plans, Adding plans allows you to:, View the formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states. Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions, Tier, Description, 1, This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2, This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 6, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. NC, NOT COVERED, – Drugs that are not covered by the plan. Code, Definition, PA, Prior Authorization, Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. , QL, Quantity Limits, Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. , ST, Step Therapy, Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. , OR, Other Restrictions, Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. , Done, Add or Remove Plans, Plans for , Select State: , Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, , Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, Non-Medicare PlansMedicare Plans, Select a box to add or remove a plan. close, Select a class to view formulary status for similar drugs, CLOSE, Additional Offers, CLOSE, Email to Patient, From:, To:, The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send, CLOSE, Email Forms to Patient, From:,